Alexander DeLuca, M.D.
Addiction, Pain, & Public Health website

[Home] [Library]  [Slides]  [Search]  [Medline]  [Links]
 

[Statements of Purpose, Ownership, Sponsorship. Privacy,  Email-confidentiality, and Advertising Policies]

 
The Endogenous Cannabinoid System Protects Against Colonic Inflammation
 

 
F. Massa1, G. Marsicano1, H. Hermann1, A. Cannich1, K. Monory1, B.F. Cravatt, G. Ferri, A. Sibaev, M. Storr and B. Lutz
;
Journal of Clinical Investigation; 113(8): 1202-1209; 2004. Posted: 2006-03-27.
[Identifier: http://www.doctordeluca.com/Library/WOD/WPS3-MedMj/CannabinoidProtectsVsColonInflam04.htm]

Related resources: 
War on Doctors / Pain Crisis Academic Literature and Reports archives
Drug War Journalism and Advocacy archives

 
See also:
WAR ON PAIN SUFFERERS Collection #3 - Medical Marijuana: 2000-2006

War on Doctors and Pain Crisis Weekly - RSS feed:
  HTML view:
Harm Reduction for Alcohol and Drug Use Disorders Weekly - RSS feed:
  HTML view:
 

 
[FULL TEXT of this article in Adobe PDF format]

Excessive inflammatory responses can emerge as a potential danger for organisms’ health. Physiological balance between pro- and anti-inflammatory processes constitutes an important feature of responses against harmful events. Here, we show that cannabinoid receptors type 1 (CB1) mediate intrinsic protective signals that counteract proinflammatory responses.

Both intrarectal infusion of 2,4-dinitrobenzene sulfonic acid (DNBS) and oral administration of dextrane sulfate sodium induced stronger inflammation in CB1-deficient mice (CB1–/–) than in wild-type littermates (CB1+/+). Treatment of wild-type mice with the specific CB1 antagonist N-(piperidino-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazole-3-carboxamide (SR141716A) mimicked the phenotype of CB1–/– mice, showing an acute requirement of CB1 receptors for protection from inflammation.

Consistently, treatment with the cannabinoid receptor agonist R(-)-7-hydroxy-{Delta}6-tetra-hydrocannabinol-dimethylheptyl (HU210) or genetic ablation of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) resulted in protection against DNBS-induced colitis. Electrophysiological recordings from circular smooth muscle cells, performed 8 hours after DNBS treatment, revealed spontaneous oscillatory action potentials in CB1–/– but not in CB1+/+ colons, indicating an early CB1-mediated control of inflammation-induced irritation of smooth muscle cells. DNBS treatment increased the percentage of myenteric neurons expressing CB1 receptors, suggesting an enhancement of cannabinoid signaling during colitis.

Our results indicate that the endogenous cannabinoid system represents a promising therapeutic target for the treatment of intestinal disease conditions characterized by excessive inflammatory responses.

[FULL TEXT of this article in Adobe PDF format]

[END]

 

Dr. DeLuca's Addiction, Pain, and Public Health Website

Alexander DeLuca, M.D.

[Top of Page]

Originally posted: 2006-03-26

All Email to: adeluca@doctordeluca.com 

Statements of Purpose, Ownership, and Sponsorship. Privacy,  Email Confidentiality, and Advertising Policies. 

Most recently revised: 2006-03-27
Copyright @ 1998-2005. All rights reserved.

We subscribe to the HONcode principles of the HON Foundation. Click to    This website is in compliance with the HONcode. Pin # = HONConduct911193. Verify HONcode Status.   We subscribe to the HONcode principles of the HON Foundation. Click to